Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Early Detection of Cancer | 31 | 2025 | 529 | 4.570 |
Why?
|
| Colorectal Neoplasms | 28 | 2025 | 627 | 4.550 |
Why?
|
| Colonoscopy | 14 | 2025 | 257 | 2.100 |
Why?
|
| Occult Blood | 15 | 2025 | 155 | 1.410 |
Why?
|
| Mass Screening | 14 | 2025 | 671 | 1.050 |
Why?
|
| Aged | 40 | 2025 | 6129 | 0.870 |
Why?
|
| Safety-net Providers | 7 | 2025 | 55 | 0.860 |
Why?
|
| Patient Compliance | 4 | 2020 | 278 | 0.860 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 380 | 0.840 |
Why?
|
| Public Health | 3 | 2020 | 82 | 0.840 |
Why?
|
| Humans | 58 | 2025 | 17376 | 0.820 |
Why?
|
| Middle Aged | 40 | 2025 | 7885 | 0.820 |
Why?
|
| Community Health Centers | 5 | 2025 | 64 | 0.790 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 142 | 0.770 |
Why?
|
| Electronic Health Records | 9 | 2020 | 707 | 0.730 |
Why?
|
| Medicaid | 7 | 2025 | 184 | 0.700 |
Why?
|
| Patient Navigation | 4 | 2025 | 19 | 0.680 |
Why?
|
| Female | 43 | 2025 | 12444 | 0.640 |
Why?
|
| Male | 42 | 2025 | 9843 | 0.630 |
Why?
|
| Postal Service | 9 | 2025 | 72 | 0.620 |
Why?
|
| Patient Selection | 3 | 2024 | 178 | 0.580 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2016 | 185 | 0.490 |
Why?
|
| Oregon | 8 | 2025 | 172 | 0.440 |
Why?
|
| Clostridium difficile | 4 | 2016 | 22 | 0.430 |
Why?
|
| Feces | 7 | 2020 | 85 | 0.420 |
Why?
|
| Qualitative Research | 5 | 2024 | 262 | 0.400 |
Why?
|
| Colonic Neoplasms | 3 | 2020 | 163 | 0.380 |
Why?
|
| Risk Assessment | 6 | 2019 | 1079 | 0.360 |
Why?
|
| Glomerular Filtration Rate | 7 | 2016 | 153 | 0.360 |
Why?
|
| Case Management | 1 | 2010 | 29 | 0.330 |
Why?
|
| Diffusion of Innovation | 1 | 2010 | 36 | 0.330 |
Why?
|
| Retrospective Studies | 16 | 2020 | 2428 | 0.330 |
Why?
|
| Evidence-Based Practice | 1 | 2010 | 55 | 0.330 |
Why?
|
| Kidney Diseases | 4 | 2010 | 51 | 0.320 |
Why?
|
| Northwestern United States | 6 | 2016 | 53 | 0.320 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 274 | 0.300 |
Why?
|
| Heart Failure | 2 | 2012 | 404 | 0.290 |
Why?
|
| Adult | 16 | 2024 | 7529 | 0.290 |
Why?
|
| Medicare | 5 | 2022 | 201 | 0.290 |
Why?
|
| Aged, 80 and over | 15 | 2016 | 1942 | 0.290 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2024 | 131 | 0.290 |
Why?
|
| United States | 14 | 2025 | 3891 | 0.290 |
Why?
|
| Attitude of Health Personnel | 3 | 2019 | 200 | 0.280 |
Why?
|
| Rural Population | 2 | 2025 | 55 | 0.280 |
Why?
|
| Ambulatory Care Facilities | 2 | 2020 | 66 | 0.260 |
Why?
|
| Primary Health Care | 5 | 2024 | 729 | 0.260 |
Why?
|
| Research Design | 3 | 2019 | 343 | 0.250 |
Why?
|
| Kidney Failure, Chronic | 3 | 2012 | 151 | 0.240 |
Why?
|
| Hospitalization | 2 | 2010 | 805 | 0.240 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 342 | 0.240 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 1155 | 0.240 |
Why?
|
| Hispanic Americans | 4 | 2016 | 378 | 0.240 |
Why?
|
| Analgesics, Opioid | 3 | 2013 | 246 | 0.240 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 702 | 0.240 |
Why?
|
| Renal Replacement Therapy | 3 | 2016 | 8 | 0.230 |
Why?
|
| Reminder Systems | 3 | 2023 | 74 | 0.230 |
Why?
|
| Data Accuracy | 1 | 2024 | 24 | 0.230 |
Why?
|
| Information Dissemination | 1 | 2024 | 51 | 0.220 |
Why?
|
| Specimen Handling | 1 | 2024 | 24 | 0.220 |
Why?
|
| Prognosis | 7 | 2020 | 604 | 0.220 |
Why?
|
| Clostridium Infections | 2 | 2016 | 13 | 0.220 |
Why?
|
| Rural Health Services | 1 | 2024 | 13 | 0.220 |
Why?
|
| Blood Pressure | 3 | 2016 | 275 | 0.210 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2014 | 13 | 0.210 |
Why?
|
| Forecasting | 2 | 2020 | 69 | 0.200 |
Why?
|
| Back Pain | 2 | 2013 | 32 | 0.200 |
Why?
|
| Anemia | 2 | 2012 | 32 | 0.170 |
Why?
|
| Precision Medicine | 1 | 2020 | 28 | 0.170 |
Why?
|
| Hemoglobins | 3 | 2016 | 37 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 205 | 0.140 |
Why?
|
| Program Evaluation | 3 | 2020 | 215 | 0.140 |
Why?
|
| Models, Statistical | 2 | 2016 | 173 | 0.140 |
Why?
|
| Neoplasms | 1 | 2022 | 448 | 0.140 |
Why?
|
| Models, Biological | 1 | 2016 | 28 | 0.130 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2017 | 61 | 0.130 |
Why?
|
| Health Maintenance Organizations | 2 | 2010 | 408 | 0.130 |
Why?
|
| Interviews as Topic | 5 | 2017 | 304 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1287 | 0.130 |
Why?
|
| Risk Management | 1 | 2016 | 4 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 15 | 0.120 |
Why?
|
| Cross Infection | 1 | 2016 | 25 | 0.120 |
Why?
|
| Cohort Studies | 8 | 2015 | 2526 | 0.120 |
Why?
|
| Risk | 2 | 2014 | 498 | 0.120 |
Why?
|
| Quality Improvement | 2 | 2020 | 190 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 366 | 0.120 |
Why?
|
| Population Surveillance | 2 | 2014 | 254 | 0.120 |
Why?
|
| Public Health Surveillance | 1 | 2014 | 43 | 0.110 |
Why?
|
| Drug Utilization | 2 | 2012 | 122 | 0.110 |
Why?
|
| Time Factors | 4 | 2019 | 1044 | 0.110 |
Why?
|
| Logistic Models | 3 | 2013 | 884 | 0.110 |
Why?
|
| Individuality | 1 | 2014 | 2 | 0.110 |
Why?
|
| Sodium | 1 | 2014 | 13 | 0.110 |
Why?
|
| Age Factors | 5 | 2016 | 884 | 0.110 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 20 | 0.110 |
Why?
|
| Referral and Consultation | 3 | 2021 | 160 | 0.110 |
Why?
|
| Cost Savings | 2 | 2011 | 21 | 0.110 |
Why?
|
| Health Literacy | 1 | 2014 | 38 | 0.110 |
Why?
|
| Perception | 1 | 2013 | 56 | 0.100 |
Why?
|
| Testosterone | 1 | 2013 | 23 | 0.100 |
Why?
|
| Erectile Dysfunction | 1 | 2013 | 24 | 0.100 |
Why?
|
| Incidence | 5 | 2020 | 1266 | 0.100 |
Why?
|
| Advisory Committees | 1 | 2014 | 112 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2014 | 228 | 0.100 |
Why?
|
| Aging | 1 | 2014 | 160 | 0.100 |
Why?
|
| Research Report | 1 | 2012 | 23 | 0.100 |
Why?
|
| Benchmarking | 1 | 2012 | 41 | 0.100 |
Why?
|
| Preventive Health Services | 1 | 2014 | 152 | 0.100 |
Why?
|
| Proteinuria | 1 | 2012 | 25 | 0.100 |
Why?
|
| Low Back Pain | 1 | 2012 | 57 | 0.100 |
Why?
|
| Text Messaging | 2 | 2025 | 34 | 0.100 |
Why?
|
| Physicians, Primary Care | 1 | 2012 | 64 | 0.090 |
Why?
|
| Health Expenditures | 1 | 2012 | 73 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2022 | 1170 | 0.090 |
Why?
|
| Laboratories | 1 | 2011 | 19 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 36 | 0.090 |
Why?
|
| Renin-Angiotensin System | 1 | 2011 | 16 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2012 | 140 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2012 | 211 | 0.090 |
Why?
|
| Telephone | 2 | 2023 | 150 | 0.090 |
Why?
|
| Systole | 3 | 2016 | 22 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 226 | 0.090 |
Why?
|
| Lisinopril | 1 | 2010 | 4 | 0.080 |
Why?
|
| California | 3 | 2025 | 2317 | 0.080 |
Why?
|
| Washington | 3 | 2019 | 385 | 0.080 |
Why?
|
| Young Adult | 5 | 2016 | 2473 | 0.080 |
Why?
|
| Hyperkalemia | 1 | 2010 | 16 | 0.080 |
Why?
|
| Phosphorus | 1 | 2009 | 6 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 84 | 0.080 |
Why?
|
| Health Services Research | 1 | 2010 | 212 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2011 | 311 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 316 | 0.080 |
Why?
|
| Colorado | 3 | 2014 | 164 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 439 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2010 | 253 | 0.070 |
Why?
|
| Comorbidity | 3 | 2014 | 564 | 0.070 |
Why?
|
| Chronic Disease | 4 | 2010 | 405 | 0.070 |
Why?
|
| Efficiency, Organizational | 1 | 2007 | 27 | 0.070 |
Why?
|
| Bone Density Conservation Agents | 1 | 2007 | 56 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2007 | 77 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2007 | 94 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 120 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 211 | 0.060 |
Why?
|
| Communication | 2 | 2019 | 181 | 0.060 |
Why?
|
| Internet | 1 | 2007 | 212 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 124 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 533 | 0.050 |
Why?
|
| Community-Institutional Relations | 1 | 2024 | 43 | 0.050 |
Why?
|
| Sex Factors | 2 | 2016 | 607 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 2 | 2012 | 15 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2012 | 231 | 0.050 |
Why?
|
| Drug Prescriptions | 2 | 2013 | 148 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 609 | 0.050 |
Why?
|
| Health Services | 2 | 2012 | 112 | 0.050 |
Why?
|
| Minority Groups | 1 | 2022 | 103 | 0.040 |
Why?
|
| Health Behavior | 2 | 2014 | 345 | 0.040 |
Why?
|
| Morbidity | 1 | 2021 | 59 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2012 | 644 | 0.040 |
Why?
|
| Risk Factors | 3 | 2014 | 3255 | 0.040 |
Why?
|
| Immunochemistry | 1 | 2020 | 18 | 0.040 |
Why?
|
| Biomarkers | 2 | 2012 | 306 | 0.040 |
Why?
|
| Adolescent | 2 | 2022 | 3533 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 64 | 0.040 |
Why?
|
| Mental Disorders | 2 | 2012 | 273 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 505 | 0.040 |
Why?
|
| Prevalence | 2 | 2013 | 839 | 0.040 |
Why?
|
| Patient Participation | 1 | 2019 | 123 | 0.040 |
Why?
|
| Organizational Culture | 1 | 2017 | 15 | 0.040 |
Why?
|
| Awareness | 1 | 2017 | 17 | 0.040 |
Why?
|
| Culturally Competent Care | 1 | 2017 | 11 | 0.040 |
Why?
|
| Leadership | 1 | 2017 | 35 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1100 | 0.030 |
Why?
|
| Health Promotion | 1 | 2019 | 278 | 0.030 |
Why?
|
| Albuminuria | 1 | 2016 | 35 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 1229 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2016 | 106 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 13 | 0.030 |
Why?
|
| British Columbia | 1 | 2015 | 3 | 0.030 |
Why?
|
| Patient Admission | 1 | 2016 | 69 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 155 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 175 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 1287 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 40 | 0.030 |
Why?
|
| Comprehension | 1 | 2014 | 18 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 86 | 0.030 |
Why?
|
| Financing, Government | 1 | 2014 | 26 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 45 | 0.030 |
Why?
|
| Creatinine | 1 | 2014 | 66 | 0.030 |
Why?
|
| Language | 1 | 2014 | 48 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 367 | 0.030 |
Why?
|
| Vardenafil Dihydrochloride | 1 | 2013 | 1 | 0.030 |
Why?
|
| Tadalafil | 1 | 2013 | 2 | 0.030 |
Why?
|
| Carbolines | 1 | 2013 | 2 | 0.030 |
Why?
|
| Sulfones | 1 | 2013 | 2 | 0.030 |
Why?
|
| Triazines | 1 | 2013 | 2 | 0.030 |
Why?
|
| Urological Agents | 1 | 2013 | 2 | 0.030 |
Why?
|
| Purines | 1 | 2013 | 3 | 0.030 |
Why?
|
| Imidazoles | 1 | 2013 | 4 | 0.030 |
Why?
|
| Sildenafil Citrate | 1 | 2013 | 4 | 0.030 |
Why?
|
| Piperazines | 1 | 2013 | 9 | 0.030 |
Why?
|
| Androgens | 1 | 2013 | 14 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 20 | 0.030 |
Why?
|
| Demography | 1 | 2012 | 96 | 0.020 |
Why?
|
| Metronidazole | 1 | 2012 | 4 | 0.020 |
Why?
|
| Vancomycin | 1 | 2012 | 4 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2012 | 93 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2014 | 315 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 33 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 73 | 0.020 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2012 | 98 | 0.020 |
Why?
|
| Health Records, Personal | 1 | 2011 | 10 | 0.020 |
Why?
|
| Outpatients | 1 | 2012 | 101 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 677 | 0.020 |
Why?
|
| Drug Overdose | 1 | 2012 | 58 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2013 | 175 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 48 | 0.020 |
Why?
|
| Patient Safety | 1 | 2011 | 38 | 0.020 |
Why?
|
| Decision Making | 1 | 2012 | 172 | 0.020 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2012 | 216 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 300 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 259 | 0.020 |
Why?
|
| Smoking | 1 | 2013 | 428 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 144 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2011 | 133 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 311 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 253 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 2011 | 309 | 0.020 |
Why?
|
| Life Style | 1 | 2011 | 316 | 0.020 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2009 | 2 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 203 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 1162 | 0.020 |
Why?
|
| Depression | 1 | 2013 | 487 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 1375 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 51 | 0.020 |
Why?
|
| Bone Density | 1 | 2007 | 94 | 0.020 |
Why?
|
| Organizations, Nonprofit | 1 | 2007 | 11 | 0.020 |
Why?
|
| Child | 1 | 2012 | 2382 | 0.020 |
Why?
|
Concepts
(236)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(10)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->